Roche's Flatiron expands oncology work to UK with collaboration deal

Health technology company Flatiron has expanded its global footprint as part of a collaboration deal with Leeds Teaching Hospitals NHS Trust, one of the largest acute hospital trusts in Europe.

The agreement for Flatiron, which is considered a leader in oncology real-world data (RWD), is a major milestone for the company in its global expansion, it said in a June 20 press release. Flatiron currently has operations in Japan, Germany and the U.K. that partner with hospitals and health networks in RWD collaborations.

Financial terms of the deal weren’t disclosed.

The goal of the partnership is to produce high-quality oncology data sets that can be used in research collaborations and under license with biopharma companies in order to speed cancer research.

“Flatiron has developed a unique offering in the U.K. to translate data from routine clinical care into research-ready datasets,” Carolyn Starrett, Flatiron’s CEO, said in the release. “We are excited to work with one of the most innovative and patient-centric medical institutions in the U.K. to add more patient experiences into the evidence that supports treatment, development, and regulatory decisions.”

Flatiron, which was bought by Roche for $1.9 billion in 2018, has been busy inking collaboration deals lately.

In May, it signed a deal with Sanofi to redesign oncology trials, and in early June the company partnered with AI-focused Lifebit to advance research and development of treatments targeting cancer.